Optimal use of medications decreases morbidity and mortality associated with a number of diseases. One of the most important factors affecting therapeutic outcomes is the dose of drugs administered to patients. The dose, however, is based on the labeled potency of each drug.
In 1986, we found that the actual concentration of gentamicin and tobramycin in different lots of vials exceeded the labeled concentration by as much as 21-34%.1 This variation prompted the publication of an article describing the ranges of amounts allowed by the 1985 United States Pharmacopeia (USP) in various antimicrobials.' The ranges of acceptable amounts could vary from 90% to 135% of the labeled amounts of antimicrobials.' Such variations may potentially lead to errors in the amount of antibiotic administered to patients. Similar data about other drugs were not reviewed. This editorial describes the percent ranges of amounts of various pharmaceuticals allowed by the 1995 USP in relation to their labeled amounts. ' 
Allowable Content for Various Drugs
The ranges of amounts permitted by the USP for various drug products currently on the US market are presented in Table 1 . The data indicate that most drugs may contain 90-110% of their labeled amounts. Antimicrobials, however, had the widest allowable range. The amounts of injectable gentamicin, tobramycin, amikacin, and vancomycin may range from 90% to 125%, 90% to 120%, 90% to 120%, and 90% to 115% of labeled content, respectively. Topical antibiotics may contain as much as 135% of the labeled amount. Aminophylline injection may contain 93-107%, while the oral theophylline products could have 94-106% to 90-110% of labeled potency. Digoxin and digitoxin injection may contain 90-105% and 90-110% of labeled content, respectively. The anticonvulsants may range from 95-105% to 90-110% of their labeled amounts. Finally, cyclosporine content may range from 90% to 110% of its labeled amount.' • Discussion Based on this review, it appears that the currently allowable amount of active component in pharmaceutical products may be as low as 90% and as high as 135% of the labeled content. In general, the range of acceptable limit was 90-110% of labeled potency, with the widest range (90-135%) observed for antimicrobials.
Even for drugs with narrow therapeutic indices such as aminoglycosides, theophylline, digoxin, anticonvulsants, cyclosporine. and methotrexate, the actual concentrations may vary widely relative to the labeled concentration. This variation is not described in the commonly used textbooks, articles, and monographs. Thus, many individuals may be unaware of this possibility. As a consequence, one is prone to erroneously assume the drug dose to be 100% of the labeled dose. Such assumptions may potentially lead to inaccurate interpretations and dosing recommendations.
Many factors may be considered in setting an acceptable range for the labeled amounts of drugs. Use of accurate, reproducible, specific methods (e.g., chemical vs. bioassays for antimicrobials) may be preferable to ensure that the pharmaceuticals contain within 5% of the labeled amounts. The shelf-life should be set to ensure interlot uniformity of the content of active component within this acceptable range. It may not be desirable to extend the MILAP C NAHATA PharmD, is Kimberly Professor of Pharmacy and Pediatrics, The Ohio State University; and Wexner Institute for Pediatric Research, Children's Hospital, Columbus, OH 43205. Reprints: Milap C Nahata PharmD. shelf life by releasing a lot of an injectable drug with a narrow therapeutic index, simply by placing 20-25% more than the labeled amount.
The drug package information and commonly used references should describe acceptable ranges. Because different lots of the same drug may contain different concentrations at a given time,' the knowledge of this variability may decrease some of the mislabeled interpatient variability observed during routine serum concentration monitoring. Although the manufacturers sponsoring research studies usually provide the drug from the same lot, different lots are often used for other clinical studies. This variability should be considered while treating patients or conducting research. The exact influence of the variability on clinicaloutcomes, however, is unknown. =:= 
